EpileaseEpilease, an anti-epileptic therapy product, is back on the market following official licensing from the VMD.

The product comes from veterinary nutraceutical expert VetPlus and contains potassium bromide, a well-established adjunctive treatment for epilepsy in dogs.

VetPlus halted the mass circulation of the product in 2011, but has now reintroduced Epilease 250mg, with the same formulation, in a blister pack of 60 capsules.


Phillipa Lomax, senior marketing manager at VetPlus, said: “Epilease is a trusted treatment for thousands of dog owners worldwide, so we are pleased to announce it is back on the market.

“We are now able to offer another treatment option, thereby improving not only seizure management in canine patients, but also aiding dogs’ and owners’ quality of life.”

View your activity >

Leave a Reply

Be the First to Comment!

Notify of


related content

The VMD has issued a product defect recall alert for specified batches of a pour-on cattle ectoparasiticide due to reported leakage problems.

2 mins

A study of dog DNA has revealed a genetic mutation linked to flat face shapes, such as those seen in pugs and bulldogs.

2 mins

Veterinary experts, doctors and scientists have come together in a one health coalition to drive the acquisition of knowledge into one of the UK’s most baffling and lethal canine diseases.

4 mins

Heart rate variability is an established risk factor for mortality in both healthy dogs and animals with heart failure, according to a study.

2 mins

Marge Chandler looks at the factors impacting on canine and feline weight gain to help equip VNs with the information they need in battling the pet bulge.

26 mins

Britain’s largest pet insurance firm is reviewing the registration process for its breeder scheme following allegations in a Sunday newspaper.

5 mins